Widespread maculopapular rash due to intramuscular interferon beta-1a during the treatment of multiple sclerosis

Multiple Sclerosis

Volumn 14, Issue 2, 2008, Pages 259-261

  Serarslan, Gamze ^a   Okuyucu, E E ^a   Melek, I M ^a   Hakverdi, S ^a   Duman, T ^a  

^a MUSTAFA KEMAL UNIVERSITY   (Turkey)

Author keywords

adverse reaction; cutaneous; interferon beta 1a; maculopapular rash; multiple sclerosis

Indexed keywords

ANTIHISTAMINIC AGENT; BETA1A INTERFERON; CETIRIZINE; CORTICOSTEROID; MOMETASONE FUROATE;

ADULT; ARTICLE; CASE REPORT; CONTROLLED STUDY; ERYTHEMA; EXOCYTOSIS; FEMALE; HISTOPATHOLOGIC SKIN REACTION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOMODULATION; INJECTION SITE ERYTHEMA; LIMB; LYMPHOCYTIC INFILTRATION; MACULOPAPULAR RASH; MULTIPLE SCLEROSIS; PRICK TEST; PRURITUS; REPEAT PROCEDURE; TRUNK;

EID: 43149093805     PISSN: 13524585     EISSN: 14770970     Source Type: Journal    
DOI: 10.1177/1352458507079945     Document Type: Article

References (12)

1. Frohman EM, Brannon K., Alexander S., Sims D., Phillips JT, O'Leary S. et al. Disease modifying agent related skin reactions in multiple sclerosis: prevention, assessment, and management. Mult Scler 2004; 10: 302-307.
2. Jacobs LD, Cookfair DL, Rudick RA, Herndon RM, Richert JR, Salazar AM et al. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. Ann Neurol 1996; 39: 285-94.
3. Webster GF, Knobler RL, Lublin FD, Kramer EM, Hochman LR Cutaneous ulcerations and pustular psoriasis flare caused by recombinant interferon beta injections in patients with multiple sclerosis. J Am Acad Dermatol 1996; 34: 365-67.
4. Cohen BA, Greenberger PA, Saini S. Delayed occurrence of a severe cutaneous reaction in a multiple sclerosis patient taking interferon beta-1b. Allergy Asthma Proc 1998; 19: 85-88.
5. Tai YJ, Tam M. Fixed drug eruption with intereron-β-1b. Australas J Dermatol 2005; 46: 154.
6. Wells J., Kossard S., McGrath M. Abdominal wall ulceration and mucinosis secondary to recombinant human interferon-beta-1b. Australas J Dermatol 2005; 46: 202-204.
7. Nousari HC, Kimyai-Asadi A., Tausk FA Subacute cutaneous lupus erythematosus associated with interferon beta-1a. The Lancet 1998; 352: 1825-26.
8. Zoguereh DD, Boucraut J., Beau-Salinas F., Bodiguel E., Lechapolis D., Pomet E. Cutaneous vasculitis with renal impairment complicating interferon-beta 1a therapy for multiple sclerosis. Rev Neurol (Paris) 2004; 160: 1081-84.
9. Kumar N., Rodriguez M. Scleromyxedema in a patient with multiple sclerosis and monoclonal gammopathy on interferon beta-1a. Mult Scler 2004; 10: 85-86.
10. Mazzeo L., Ricciardi L., Fazio MC, Fogliani O., Fedele R., Ferlazzo E., Isola S. Severe urticaria due to recombinant interferon beta-1a. Br J Dermatol 2003; 148: 172.
11. Dereure O., Raison-Peyron N., Larrey D., Blanc F., Guilhou J-J. Diffuse inflammatory lesions in patients treated with interferon alfa and ribavirin for hepatitis C: a series of 20 patients. Br J Dermatol 2002; 147: 1142-46.
12. Barboud A., Goncalo M., Bruynzeel D., Bircher A.; European Society of Contact Dermatitis. Guidelines for performing skin tests with drugs in the investigation of cutaneous adverse drug reactions. Contact Dermatitis 2001; 45: 321-28.